CN103852465A - Method and apparatus for detecting marker protein - Google Patents
Method and apparatus for detecting marker protein Download PDFInfo
- Publication number
- CN103852465A CN103852465A CN201210505981.6A CN201210505981A CN103852465A CN 103852465 A CN103852465 A CN 103852465A CN 201210505981 A CN201210505981 A CN 201210505981A CN 103852465 A CN103852465 A CN 103852465A
- Authority
- CN
- China
- Prior art keywords
- mark
- bonding agent
- sample solution
- antibody
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
Abstract
A method for detecting marker protein comprises: contacting a sample solution containing the marker protein and a marker binding agent bindable with the marker of the marker protein; contacting the sample solution with a binding substance, wherein the binding substance is bindable with the marker binding agent unbound with the marker; and based on the marker signal variation caused by contact of the sample solution and the binding substance, determining the concentration of the marker protein in the sample solution. The invention also relates to an apparatus for detecting the marker protein.
Description
Technical field
The present invention relates to the method and apparatus of certification mark albumen.
Background technology
Labelled protein is very noticeable in protein expression and purifying.In view of the application sustainable growth of labelled protein in 26S Proteasome Structure and Function research, need the method that can detect labelled protein rapidly, expediently.
At present, the detection of labelled protein in complex mixture is needed at least two hours conventionally, thereby it is tediously long usually to seem.The example of existing detection method has ELISA, detected by Western blot and based on specific painted method.One of aforementioned last class methods is exemplified as the InVision that carries out specific and responsive dyeing for oligo-histidine mark fusion
tMdyeing in oligo-histidine mark gel, classification number LC6030, LC6033.According to (being revised on March 19th, 2012 from the retrievable operation instruction of interconnected network address http://tools.invitrogen.com/content/sfs/manuals/invisionstain_m an.pdf, publication number is 25-0671), for the dyeing of oligo-histidine mark fusion at least needs 2 hours 20 minutes for detecting.
Therefore, be necessary to develop method and apparatus new or improved certification mark albumen.
Summary of the invention
The object of this invention is to provide a kind of method and apparatus newly or improved certification mark albumen.
On the one hand, the method the present invention relates to comprises: the sample solution that comprises labelled protein is contacted with the mark bonding agent that can combine with the mark of this labelled protein; This sample solution is contacted with bond, and this bond can combine with the mark bonding agent of not being combined with mark; And, contact caused id signal according to this sample solution with bond and change, determine the concentration of labelled protein in this sample solution.
On the other hand, the device the present invention relates to comprises: test-strips, and it comprises: sample reception area, to receive the sample solution that comprises labelled protein; Land, it comprises the mark bonding agent that can be combined with the mark of this labelled protein; And detection zone, it comprises the bond that can combine with the mark bonding agent of not being combined with mark.
The method and apparatus of certification mark albumen involved in the present invention has solved the technical matters of prior art.
Accompanying drawing explanation
Be described for embodiments of the invention in conjunction with the drawings, the present invention may be better understood, in the accompanying drawings:
Fig. 1 is the schematic perspective view of the test-strips of the device that provided according to one embodiment of present invention.
Fig. 2 is the diagrammatic cross-section of test-strips in Fig. 1.
Fig. 3 is the photo obtaining in example 5.
Fig. 4 is the chart obtaining in example 5.
Fig. 5 is the photo obtaining in example 6.
Embodiment
Approximate term in instructions is used for modifying quantity, represents that the present invention is not limited to this concrete quantity, also comprises approach to this quantity acceptable and can not cause the part of the correction of the change of relevant basic function.Accordingly, modify a numerical value with " approximately ", " approximately " etc., mean and the invention is not restricted to this accurate numerical value.In some example, approximate term may be corresponding to the precision of the instrument of measurement numerical value.
In the following description book and claim, unless clearly pointed out in addition, single plural number is not limited.
Mentioned " can ", " can ", " possibility " and " can be " of the application is illustrated in the possibility occurring under certain environment; There is the character of appointment, the possibility of feature or function; And/or by showing that one or more ability, performance are suitable for another kind of action, or the relevant possibility of the action applicable to this.Therefore, the term that represents modification for " can ", " can ", " possibility " and " can be " obviously applicable, can or be suitable for represented ability, function, or purposes, consider in some cases simultaneously, the term of modifying may be not suitable for sometimes, can not or improper.For example, in some cases, event or ability may be desired, and in other cases, this event or ability can not occur.This difference is contained by term " can ", " can ", " possibility " and " can be ".
The method the present invention relates to can be used for existence and/or the quantity of labelled protein in test sample solution, that is, and and the concentration of labelled protein.
Sample solution may be any solution that comprises labelled protein.Sample solution may be the solution making with labelled protein.In certain embodiments, sample solution can be obtained with for example phosphate buffered solution buffering dilution by the labelled protein sample of purifying.
" labelled protein " that the present invention mentions represents the albumen that comprises mark.The example of mark includes but not limited to, FC, thioredoxin, NusA and the albumin of oligo-histidine, glutathione sulfurtransferase, polypeptide marker thing, strepto-binding peptide II, maltose-binding protein, hemagglutinin, proto-oncogene, T7 mark, S mark, calmodulin binding peptide, class elastin laminin polypeptide, antibody are in conjunction with territory.The example of labelled protein includes but not limited to oligo-histidine labelled protein and has the human body antibody of FC.
After the sample solution that comprises labelled protein contacts with mark bonding agent, mark is combined with this mark bonding agent." the mark bonding agent " in the present invention, mentioned refers to the bonding agent of being combined with marker.This mark bonding agent can combine with the mark of labelled protein.The example of bonding agent includes but not limited to, antibody, antibody fragment or fit.In certain embodiments, bonding agent is the specific antibody of mark, the specific antibody of for example oligo-histidine, or for the non-human antibody of specificity of human body antibody FC.One of the specific antibody of oligo-histidine is exemplified as and can determines mark (rabbit) antibody, product code numbering 600-401-382 from the anti-6X oligo-histidine antigen obtaining as Pennsylvania, America Gilbertsville city Rockland Immunochemicals Inc..Being exemplified as for of the non-human antibody of specificity of human body antibody FC can be from anti-human body IgG FC (goat) antibody obtaining as Pennsylvania, America Gilbertsville city RocklandImmunochemicals Inc., product code numbering 609-1103.
Marker may be marker any physics that can be detected by vision-based detection or optical instrument or chemistry.Marker for example may be, by reacting colorific enzyme-substrate combination, coloured particulate (rubber particle), colloidal metal, metal melten gel, carbon melten gel, fluorescent material and lipid somatocyst or polymerization somatocyst.Marker source example includes but not limited to, collaurum, latex bead, fluorescent microsphere, magnetic bead, quantum dot and frequency upconversion phosphorus.In certain embodiments, marker derives from collaurum.
In the time that sample solution is contacted with bond, if there is the mark bonding agent of not being combined with mark, this mark bonding agent is combined with bond, changes thereby produce id signal before and after contact.
" bond " that the present invention mentions refers to the material that can combine with the mark bonding agent of not being combined with mark.In certain embodiments, bond is a kind of material (as peptide, albumen or microballoon) that is different from labelled protein, but comprises this mark.In certain embodiments, bond is mark.
Because the intensity of signal is relevant with the quantity of marker, thus with sample solution in the concentration negative correlation of labelled protein, therefore the concentration of labelled protein can be by such as vision or use the signal intensity that spectroscopy detects to determine.In the time using spectroscopy, can set up a calibration curve, for quantizing the concentration of labelled protein.
In certain embodiments, sample solution, after contacting with bond, contacts with control thing.
" the control thing " mentioned in the present invention refers to a kind of material that can combine with mark bonding agent.In certain embodiments, controlling thing is the bonding agent for the non-human antibody of the bonding agent of human body antibody FC.An example for the bonding agent of the non-human antibody of the bonding agent of human body antibody FC is can be from anti-goat IgG FC (rabbit) antibody obtaining as Pennsylvania, America Gilbertsville city Rockland Immunochemicals Inc., product code numbering 105-4103.Anti-goat antibody guarantees that only the pairing antibody from goat can be trapped.From the antibody of other species beyond goat to also using.
Albumin A or G both can with anti-human body IgG(goat) and so on antibody be combined, also can combine with any human body IgG analyte, thus can as control thing.In certain embodiments, to control thing be albumin A or its IgG in conjunction with variant, Protein G or its IgG in conjunction with variant and albumen L or its IgG in conjunction with at least one in variant.In certain embodiments, controlling thing and only have one, is albumin A.
An example of albumin A can be obtained from medical treatment Biological Science Co., Ltd of New Jersey General Electric, and production number is 17-0872-02.The IgG of albumin A is exemplified as the MabSelect SuRe that can obtain from medical treatment Biological Science Co., Ltd of New Jersey General Electric in conjunction with of variant
tMpart.An example of Protein G can be obtained from medical treatment Biological Science Co., Ltd of New Jersey General Electric, and production number is 17-0619-09.
Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings, will can not describe well-known function and structure in detail, to avoid becoming puzzling because unnecessary details makes the present invention.
Please refer to Fig. 1 and Fig. 2, a test-strips 1 of the device providing according to one embodiment of present invention comprises: for receiving the sample reception area 2 of the sample solution that comprises labelled protein; The land 3 that comprises the mark bonding agent that can be combined with the mark of labelled protein; With the detection zone 4 that comprises the bond that can combine with the mark bonding agent of not being combined with mark.
In certain embodiments, sample solution can be diffused through to land 3 and detection zone 4 to contact with mark bonding agent and bond.Correspondingly, the concentration of labelled protein can diffuse through 4 front and back, detection zone according to the sample solution that comprises labelled protein, and the signal intensity of detection zone 4 is determined.
In certain embodiments, sample reception area 2 may be by glass fibre bar is immersed in a kind of phosphate buffered solution comprising such as bovine serum albumin(BSA), polysorbas20, and after saturated this glass fibre bar is a dry and sample pad making.
Can be by such as sample solution being dropped in to sample solution reception area 2 or the medium mode of sample solution being immersed in sample reception area 2, thus sample solution is contacted with sample reception area 2.
Sample solution spreads forward by capillary action from sample reception area 2.In the time that sample solution diffuses through land 3, mark bonding agent discharges from land 3 with diffusion forward together with sample solution.The mark of labelled protein is combined with some mark bonding agents.
In certain embodiments, land 3 may be to be dried the pad making after absorbing binding soln with a glass fibre bar.This binding soln comprises mark bonding agent.
In the time that sample solution diffuses through detection zone 4, some mark bonding agents of not being combined with mark are combined with bond, and rest on detection zone 4.
The signal that the marker of detection zone 4 produces can be observed or be used optical instrument to detect by bore hole.
In certain embodiments, mark bonding agent is colored, and in sample solution, the concentration of labelled protein is determined according to the change color of detection zone 4.In certain embodiments, the color of detection zone 4 is along with the increase of the concentration of labelled protein in sample solution or minimizing and change.Therefore, the existence of labelled protein and/or quantity can be determined by the variation that detects color.
For example, if there is no labelled protein in sample solution, the color of detection zone 4 increases to the strongest because can stop from the mark bonding agent of land 3 all rest on detection zone 4.Similarly, if the color of the detection zone of the first test-strips is darker than the color of the detection zone of the second test-strips, in the first sample solution detecting by the first test-strips, the concentration of labelled protein is lower than the concentration of labelled protein in the second sample solution detecting by the second test-strips, and vice versa.The variation of color can be observed or be used spectroscopy to detect by vision.
In certain embodiments, in detection zone 4, the signal intensity of marker can detect by optical instrument.The signal intensity of detection zone 4 may be the output of this optical instrument.In certain embodiments, signal intensity is the height of test-strips reader output signal peak.
The solution of known mark protein concentration is spread and detects in test-strips to the signal intensity of corresponding detection zone, can set up the function formula between concentration and the detection zone signal intensity of labelled protein.In sample to be tested solution, the concentration of labelled protein can be by being used this function formula and the corresponding signal intensity of the detection zone 4 recording to calculate.
In certain embodiments, test-strips 1 comprises and comprises the control zone 5 of controlling thing.Sample solution is by the backward front diffusion in detection zone 4, and the mark bonding agent not stopping in detection zone 4 is combined with the control thing of control zone 5, rests on control zone 5.
The signal that identifies deposits yields in control zone 5 can be observed or be used optical instrument to detect by bore hole.In some embodiment, what the generation of control zone 5 signals showed that sample solution spreads to control zone 5 from detection zone 4 completes.In some embodiment, if all mark bonding agents all rest on detection zone 4, marker can not be detected in control zone 5.In some embodiment, as fruit part mark bonding agent rests on detection zone 4, because the marker quantity positive correlation of the concentration of labelled protein and control zone 5, so the quantity of the marker that control zone 5 records can be used for improving the accuracy of detection of mark protein concentration in sample solution.
In certain embodiments, test-strips 1 comprises uptake zone 6, and it is near apart from detection zone 4 apart from control zone 5 ratios.
Test-strips 1 may be to comprise any absorbent material, and can allow the long strips of sample solution diffusion.The sample reception area 2 of test-strips 1, land 3, detection zone 4, control zone 5 can be made from the same material or a different material with uptake zone 6.The sample uptake zone 2 of test-strips 1, land 3, detection zone 4, control zone 5 are one-body molded or fit together with uptake zone 6.
In certain embodiments, sample reception area 2, land 3, film 7 fit together with uptake zone 6.In some embodiment, land 3 is overlapping with sample reception area 2 and film 7, and film 7 is also overlapping with uptake zone 6.
In certain embodiments, test-strips 1 may comprise one by such as plastic material as polyester
or the supporting pad 8 made of polyethylene terephthalate (PET), to support sample reception area 2 placed on it, land 3, detection zone 4, control zone 5 and uptake zone 6.
In certain embodiments, may provide a plastic casing (not diagram) so that test-strips 1 is wrapped in wherein.In certain embodiments, sample reception area 2 may be positioned at outside plastic casing.
By method of the present invention, sample solution is contacted with bond with mark bonding agent, and change according to the id signal before and after contact bond the concentration of determining labelled protein, the used time is very short.Therefore, this method is simply rapid.Mark bonding agent and bond are at least generally suitable for a series of albumen that comprise specific markers, therefore in the time needing to detect any this series albumen that comprises this specific markers, test-strips 1 is without replacing; Therefore can save the cost of design and manufacturing test bar 1.
Example
Following experimental example is implemented to the invention provides further guidance for those skilled in the art.Example does not limit the scope of the present invention defining in claims.
Example 1
The preparation of pad
By (1 milliliter of gold-nanoparticles solution, gold-nano particle, 40 nanometers) (from Shanghai City, China Shanghai Quicking Biotech Co., Ltd.) inject micro-centrifuge tube of 1.5 milliliters, then add 5 microlitre 0.2 mol/L solution of potassium carbonate (from Shanghai City, China Chemical Reagent Co., Ltd., Sinopharm Group), vibration is fully to mix.Add again 4 other microliters of mouse oligo-histidine labeled monoclonal antibody (oligo-histidine antibody) (5 mg/ml, from Shanghai City, China Ai Bimate biological medicine (Shanghai) Co., Ltd.) after, this solution that vibrates immediately, then waits for that 10 minutes to obtain binding soln.
Then the speed centrifuging that, binding soln turns with per minute 11,000 10 minutes.Remove after supernatant liquor, the aaerosol solution again of the phosphate buffered solution (being made in water by dibastic sodium phosphate, sodium dihydrogen phosphate and sodium chloride) of the pH7.4 of 0.01 mol/L that 100 microlitres are contained to 1/1000 bovine serum albumin(BSA) (from Belgian Acros Organics) injects micro-centrifuge tube, again dissolves the oligo-histidine antibody (being nanogold particle-oligo-histidine antibody) of being combined with colloid gold particle.Be combined with 180 microlitres in micro-centrifuge tube of dilution (the 0.01 mol/L phosphate buffered solution that contains 3% trehalose, 0.5% bovine serum albumin(BSA) and 1% polysorbas20) and insert (0.8 centimetre wide × 4 centimeter length of a 33Glass glass fibre comprising 20 microlitre nanogold particle-oligo-histidine antibody, obtain from the medical treatment Biology Science Co., Ltd of General Electric of New Jersey), after 1-2 minute, all solution is evenly absorbed by this 33Glass glass fibre.After it is dried to 3 hours with 37 degrees Celsius in drying oven, obtaining can be for the pad of follow-up test bar assembling.
Example 2
The preparation of sample pad
A 33Glass glass fibre (1.5 centimetres wide × 4 centimeter length) is immersed in the sample pad solution being made up of the 0.1 mol/L phosphate buffered solution that contains 1% bovine serum albumin(BSA) and 0.5% polysorbas20, until fully infiltration.After it is dried to 3 hours with 37 degrees Celsius in drying oven, obtaining can be for the sample pad of follow-up test bar assembling.
Example 3
The preparation of the film that contains T line and C line
C line solution is by 20 microlitre 3 mg/ml albumin As (from Long Ji Bioisystech Co., Ltd of Hangzhou China city) are mixed to the 1 mg/ml albumin A solution making with 40 microlitre 0.01 mol/L phosphate buffered solution (pH7.2).
Oligo-histidine mark green fluorescent protein (1 mg/ml, overexpression in Escherichia coli) is used as T line solution.
By nitrocellulose membrane 7(FF120HP, from medical treatment Biology Science Co., Ltd of New Jersey General Electric) be bonded at the sticking plastic support pad of a tool 8(DB-6, from the outstanding Bioisystech Co., Ltd in Shanghai, Shanghai City, China) on.
With distribution platform (California, USA Irving city BioDot Inc.) by T line solution and C line solution with 0.5 microlitre/centimetre speed be added in respectively on FF120HP film, to form respectively detection zone 4 and control zone 5.
Example 4
The assembling of bar
The pad 6(470 that cotton can be absorbed water, from New Jersey General Electric medical treatment Biology Science Co., Ltd) be attached on the sticking supporting pad 8 of tool, and with example 3 in be bonded at the overlapping 1-2 millimeter of FF120HP film 7 on supporting pad 8.
In example 1, the pad 3 of preparation is contained in other one side of film 7, has overlapping of 1-2 millimeter with film 7, and sample pad 2 has overlapping of 1-2 millimeter with pad 3.
Combination bar is by Jin Biao bio tech ltd, Shanghai, gold mark cutter ZQ2000(Shanghai City, China) cut into the rectangular of 4 mm wides as depicted in figs. 1 and 2, test for aftermentioned.
Example 5
The detection of oligo-histidine mark green fluorescent protein
The oligo-histidine albumen sample (overexpression in Escherichia coli) of purifying is diluted to 0 mg/ml by 10 mM/ls of phosphate buffers respectively, 0.268 mg/ml, 0.536 mg/ml, 1.072 mg/ml.Every kind of standard solution of the dilution gained of 150 microlitres is added into a hole of 96 orifice plates, then in four holes, inserts respectively a test-strips and erects, and sample solution can upwards be spread along test-strips.These test-strips are prepared similar with in example 4, but on film, there is no C line.
After 10 minutes, these test-strips are removed, and its photo as shown in Figure 3.In Fig. 3, test-strips I puts into not containing that of the phosphate buffer hole of 0.01 mole of oligo-histidine labelled protein, test-strips II is that of the phosphate buffer hole of 0.01 mole of putting into 0.268 mg/ml oligo-histidine labelled protein, test-strips III is that of the phosphate buffer hole of 0.01 mole of putting into 0.536 mg/ml oligo-histidine labelled protein, and test-strips IV is that of the phosphate buffer hole of 0.01 mole of putting into 1.072 mg/ml histidine tagged proteins.Can be as can be seen from Figure 3, in test-strips, the color of T line 4 shoals along with the increase of oligo-histidine labelled protein concentration, and namely, the color of the T line of test-strips I is the darkest, and the T line color of test-strips IV is the most shallow.
Test-strips is placed on Jin Biao bio tech ltd, Shanghai, gold label test strip reader DT2030(Shanghai City, China), read the quantitative signal based on T line signal intensity.Figure 4 shows that in test-strips that T line peak value is with respect to the calibration curve of oligo-histidine labelled protein sample concentration.
Example 6
Experiment in example 5 repeats in this example, but diffuse to test-strips V, and the concentration of the sample solution of VI and VII is different from example 5, and in this example test-strips all containing C line.
In Fig. 5, show the photo that contains 3 test-strips, wherein, what test-strips V immersed is the 0.01 mol/L phosphate buffered solution that does not contain oligo-histidine labelled protein completely, what test-strips VI immersed is the 0.01 mol/L phosphate buffered solution that contains 3 grams per liter oligo-histidine labelled proteins, and what test-strips VII immersed is the 0.01 mol/L phosphate buffered solution that contains 5 grams per liter oligo-histidine labelled proteins.The result of Fig. 5 shows under experiment condition, and the upper limit of detection of oligo-histidine mark green fluorescent protein can exceed 3 mg/ml.
Although Partial Feature of the present invention is had been described in detail and is described in embodiment, do not departing under the prerequisite of spirit of the present invention, can carry out various changes and replacement to the present invention.Same, those skilled in the art also can obtain other change disclosed by the invention and equivalent according to normal experiment.All these change, and replacement and equivalent are all within the design and scope of the defined claim of the present invention.
Claims (12)
1. a method for certification mark albumen, is characterized in that, comprising:
The sample solution that comprises labelled protein is contacted with the mark bonding agent that can combine with the mark of this labelled protein;
This sample solution is contacted with bond, and this bond can combine with the mark bonding agent of not being combined with mark; And,
Contact caused id signal according to this sample solution with bond and change, determine the concentration of labelled protein in this sample solution.
2. the method for certification mark albumen as claimed in claim 1, is characterized in that, it comprises:
The test-strips with sample reception area, land and detection zone is provided, and wherein, land comprises this mark bonding agent, and detection zone comprises this bond;
This sample solution that comprises labelled protein is spread and pass through sample reception area, land and detection zone; With
Spread and pass through the caused id signal variation in detection zone according to this sample solution that comprises labelled protein, determining the concentration of labelled protein in this sample solution.
3. the method for certification mark albumen as claimed in claim 2, is characterized in that, the described concentration according to labelled protein in definite this sample solution of id signal variation refers to the change color according to detection zone.
4. a device for certification mark albumen, it comprises:
Test-strips, it comprises:
Sample reception area, to receive the sample solution that comprises labelled protein;
Land, it comprises the mark bonding agent that can be combined with the mark of this labelled protein; With
Detection zone, it comprises the bond that can combine with the mark bonding agent of not being combined with mark.
5. the device of certification mark albumen as claimed in claim 4, it is characterized in that, described test-strips comprise comprise can with the control zone of the control thing that be combined of mark bonding agent, described control thing is albumin A or its IgG in conjunction with variant, Protein G or its IgG in conjunction with variant, albumen L or its IgG in conjunction with variant and at least one in the bonding agent of the non-human antibody of the bonding agent of human body antibody FC.
6. device as claimed in claim 4, is characterized in that, described mark bonding agent comprises at least one the marker deriving from collaurum, latex bead, fluorescent microsphere, magnetic bead, quantum dot and frequency upconversion phosphorus.
7. device as claimed in claim 4, is characterized in that, described mark bonding agent comprise comprise antibody, antibody fragment or fit at least one bonding agent.
8. the device of the certification mark albumen as described in arbitrary claim in claim 4 to 7, it is characterized in that, described mark is that FC, class elastin laminin polypeptide, thioredoxin, NusA and the albumin of oligo-histidine, glutathione sulfurtransferase, polypeptide marker thing, strepto-binding peptide II, maltose-binding protein, hemagglutinin, proto-oncogene, T7 mark, S mark, calmodulin binding peptide, antibody is in conjunction with at least one in territory.
9. the device of certification mark albumen as claimed in claim 8, is characterized in that, described test-strips comprises the control zone that comprises the control thing that can be combined with mark bonding agent, and described control thing is albumin A.
10. the device of certification mark albumen as claimed in claim 9, is characterized in that, described mark is oligo-histidine, and mark bonding agent comprises oligo-histidine antibody.
The device of 11. certification mark albumen as claimed in claim 10, is characterized in that, described mark bonding agent comprises the marker that derives from collaurum.
The device of 12. certification mark albumen as claimed in claim 8, wherein mark is the FC of human body antibody, and mark bonding agent comprises the antibody of the FC of human body antibody, described test-strips comprise comprise can with the control thing that be combined of mark bonding agent, wherein control thing and be the bonding agent for the non-human antibody of the bonding agent of human body antibody FC.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210505981.6A CN103852465A (en) | 2012-11-30 | 2012-11-30 | Method and apparatus for detecting marker protein |
| PCT/SE2013/051404 WO2014084789A1 (en) | 2012-11-30 | 2013-11-28 | Method and apparatus for detection of tagged protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210505981.6A CN103852465A (en) | 2012-11-30 | 2012-11-30 | Method and apparatus for detecting marker protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103852465A true CN103852465A (en) | 2014-06-11 |
Family
ID=50828280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210505981.6A Pending CN103852465A (en) | 2012-11-30 | 2012-11-30 | Method and apparatus for detecting marker protein |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103852465A (en) |
| WO (1) | WO2014084789A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108700A (en) * | 2014-12-17 | 2017-08-29 | 通用电气医疗集团生物工艺研发股份公司 | The κ light chain Binding peptides of modification |
| CN107442186A (en) * | 2016-05-31 | 2017-12-08 | 陈欲超 | Micro-fluidic chip, the analytical equipment based on micro-fluidic chip and analysis method |
| CN107449631A (en) * | 2016-05-31 | 2017-12-08 | 陈欲超 | Sampler, analytical equipment and analysis method |
| CN111504923A (en) * | 2020-04-16 | 2020-08-07 | 武汉大学 | Method for measuring protein content in chitin derivative |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109964127A (en) * | 2016-08-23 | 2019-07-02 | Qoolabs有限公司 | For assessing the lateral flow detection of recombinant protein expression or reporter gene expression |
| CN109212231A (en) * | 2018-09-14 | 2019-01-15 | 武汉优恩生物科技有限公司 | One kind being based on SFTS recombinant proteins nanoparticle immunologic detection method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559007A (en) * | 2000-12-12 | 2004-12-29 | 澳大利亚海洋科学研究院 | Assay for paralytic shellfish toxin |
| CN1745300A (en) * | 2002-06-12 | 2006-03-08 | 塞诺菲-安万特德国有限公司 | HTS-capable method and testing system for determining the interaction between a C-reactive protein and constituents that bind to a C-reactive protein |
| WO2006036212A2 (en) * | 2004-04-22 | 2006-04-06 | Medtox Scientific, Inc. | Non-sugar sweeteners for use in test devices |
| CN101839908A (en) * | 2010-05-28 | 2010-09-22 | 李金波 | Quantitative detection device and detection method of biological fluid samples |
| WO2012021741A2 (en) * | 2010-08-12 | 2012-02-16 | Clontech Laboratories, Inc. | Lateral flow assays for non-diagnostic analytes |
-
2012
- 2012-11-30 CN CN201210505981.6A patent/CN103852465A/en active Pending
-
2013
- 2013-11-28 WO PCT/SE2013/051404 patent/WO2014084789A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559007A (en) * | 2000-12-12 | 2004-12-29 | 澳大利亚海洋科学研究院 | Assay for paralytic shellfish toxin |
| CN1745300A (en) * | 2002-06-12 | 2006-03-08 | 塞诺菲-安万特德国有限公司 | HTS-capable method and testing system for determining the interaction between a C-reactive protein and constituents that bind to a C-reactive protein |
| WO2006036212A2 (en) * | 2004-04-22 | 2006-04-06 | Medtox Scientific, Inc. | Non-sugar sweeteners for use in test devices |
| CN101839908A (en) * | 2010-05-28 | 2010-09-22 | 李金波 | Quantitative detection device and detection method of biological fluid samples |
| WO2012021741A2 (en) * | 2010-08-12 | 2012-02-16 | Clontech Laboratories, Inc. | Lateral flow assays for non-diagnostic analytes |
Non-Patent Citations (3)
| Title |
|---|
| BIING-HUI LIU等: "Development of a Monoclonal Antibody against Ochratoxin A", 《ANAL. CHEM.》 * |
| GANG LIU等: "Rapid and sensitive quantitation of zearalenone in food and feed by lateral flow", 《FOOD CONTROL》 * |
| 方菲: "纳米金免疫层析法定量检测肿瘤标志物的研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108700A (en) * | 2014-12-17 | 2017-08-29 | 通用电气医疗集团生物工艺研发股份公司 | The κ light chain Binding peptides of modification |
| CN107442186A (en) * | 2016-05-31 | 2017-12-08 | 陈欲超 | Micro-fluidic chip, the analytical equipment based on micro-fluidic chip and analysis method |
| CN107449631A (en) * | 2016-05-31 | 2017-12-08 | 陈欲超 | Sampler, analytical equipment and analysis method |
| CN107442186B (en) * | 2016-05-31 | 2020-06-09 | 深圳汇芯生物医疗科技有限公司 | Microfluidic chip, analysis device based on microfluidic chip and analysis method |
| CN111504923A (en) * | 2020-04-16 | 2020-08-07 | 武汉大学 | Method for measuring protein content in chitin derivative |
| CN111504923B (en) * | 2020-04-16 | 2021-09-14 | 武汉大学 | Method for measuring protein content in chitin derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014084789A1 (en) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103852465A (en) | Method and apparatus for detecting marker protein | |
| CN1125983C (en) | Analytical device for membrane-based assays | |
| CA2344544A1 (en) | Analytical test device and method of use | |
| JPH10300750A (en) | Oxygen immunoassay and test piece | |
| US11852630B2 (en) | Immunochromatographic test piece | |
| JPWO2003014740A1 (en) | Biosensor and measurement method | |
| CN102667479B (en) | The film biology sensor being attached with porous film and the immune response utilizing this film biology sensor or enzyme reaction assay method | |
| WO2009136477A1 (en) | Biosensor | |
| AU2020201874A1 (en) | Immunoassay utilizing trapping conjugate | |
| JP7451431B2 (en) | Systems, devices and methods for amplifying signals in lateral flow assays | |
| CN102879583A (en) | Test card for rapidly diagnosing pancreatic trauma and acute pancreatitis and preparation method thereof | |
| EP3404413B1 (en) | Glycated protein assay | |
| US20180024129A1 (en) | Lateral flow device and method of use | |
| CN105021823A (en) | Immunochromatographic analysis device, immunochromatographic analysis method, and immunochromatographic analysis kit | |
| CN104849264B (en) | A kind of chemiluminescence immunoassay strip and preparation method thereof | |
| KR102331684B1 (en) | Method for assaying creatine kinase mb isozyme and kit to be used therein | |
| CN103940990A (en) | Sensitivity-enhanced gold-labeled immunochromatographic strip and preparation method thereof | |
| CN103376327A (en) | Method for detecting concentration of antibody or fusion protein | |
| CN210487791U (en) | Quantum dot immunochromatography test strip | |
| JP7181547B2 (en) | Test strip for immunochromatography and method for detecting substance to be detected | |
| JP2019015583A (en) | Immuno-chromatographic test piece | |
| JP4544907B2 (en) | Device and detection method | |
| JP2009258136A (en) | Device and detection method | |
| JP6039965B2 (en) | Immunochromatography device | |
| CN220323330U (en) | Device for rapidly detecting cathepsin Z |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140611 |
|
| WD01 | Invention patent application deemed withdrawn after publication |